Inhibikase Therapeutics, Inc. (Nasdaq: IKT), a clinical-stage pharmaceutical company, has announced the publication of its Phase 1 clinical studies for risvodetinib (risvo), a potential disease-modifying therapy for Parkinson’s disease and related disorders. The study, published in the Journal of Parkinson’s Disease, marks a significant advancement in Parkinson’s disease treatment.

The Phase 1 study evaluated the safety, tolerability, and pharmacokinetics of risvo in both healthy volunteers and participants with Parkinson’s disease. The multi-part study, involving 94 healthy volunteers and 14 Parkinson’s patients, assessed risvo under various dosing conditions, highlighting its favorable safety and tolerability profile.

Risvo demonstrated linear pharmacokinetics and crossed the blood-brain barrier, a crucial factor in treating neurological disorders. Importantly, the drug was persistently present in the central nervous system, as indicated by its concentration in cerebrospinal fluid (CSF). The trials reported only minor adverse events, underscoring risvo’s potential as a safe treatment option.

Inhibikase continues its Phase 2 201 Trial, focusing on risvo in untreated Parkinson’s disease patients. As of January 29, 2024, 45 participants have been enrolled, with 19 completing the 12-week dosing period. The trial’s progress, with only a few mild and moderate adverse events reported, is promising for risvo’s future in Parkinson’s disease treatment.

Dr. Milton Werner, President and CEO of Inhibikase, emphasized the importance of the c-Abl kinase in Parkinson’s disease processes and expressed optimism about risvo’s potential based on the early clinical work.

The Phase 1 clinical studies of risvodetinib represent a hopeful development in the fight against Parkinson’s disease. With its favorable safety profile and potential efficacy, risvo stands out as a promising candidate in modifying the course of this debilitating neurodegenerative disease.

Inhibikase Therapeutics’ risvodetinib showcases significant potential in altering the landscape of Parkinson’s disease treatment. The drug’s ability to penetrate the blood-brain barrier and its favorable safety profile in early trials indicate a promising future in neurodegenerative disease therapeutics. The ongoing Phase 2 trials could further solidify risvo’s role in providing a much-needed therapeutic option for Parkinson’s disease patients.

  Dr. Milton Werner, Inhibikase Therapeutics, Parkinson’s disease, risvodetinib